Loss of heterozygosity on chromosome 12, region 2

Loss of heterozygosity on chromosome 12, region 2 (abbreviated as LOH12CR2 or LOH2CR12) designates a genomic region where one homologous segment of DNA has been lost during cancer progression, resulting in the loss of genetic variability at that locus[2][3][4]. This loss may unmask pathogenic mutations (such as in tumor suppressor genes) or result in haploinsufficiency, contributing to tumorigenesis. LOH is a cytogenetic event, not a protein, gene, or receptor; therefore, this designation is not a therapeutic target but reflects a genetic event frequently observed in cancers[1][4]. Identifying LOH can help guide cancer research or diagnostics, especially when the chromosomal interval contains or overlaps with known cancer susceptibility loci, but "LOH12CR2" per se is not a druggable molecule or defined molecular entity. Summary of key points: - LOH12CR2 refers to a chromosomal region and an event (loss of heterozygosity) rather than a canonical molecule. - It is relevant in cancer biology for mapping tumor suppressor gene loss but is not a drug target, receptor, or protein. - No standard molecular classification, aliases are all variants describing the same chromosomal event. - Not to be confused with protein-coding genes or biological targets.

Other names

LOH12CR2LOH2CR12Loss of heterozygosity, 12, chromosomal region 2 (non-protein coding)Loss of heterozygosity on chromosome 12, region 2